Topic:

Manufacturing

Latest Headlines

Latest Headlines

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1 (Part 3)

FiercePharmaAsia  combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1 (Part 2)

FiercePharmaAsia  combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.

Singapore's Temasek piles into Indian pharma to the tune of $567.7M

Sun Pharmaceutical Industries, Glenmark Pharmaceuticals and Intas Pharmaceuticals, all India-based, are getting a collective investment infusion of $567.7 million, all from Singapore's government.

China on standardized quality push for traditional medicines

China's government at the highest level is taking steps to bring the traditional Chinese medicine industry into the 21st century with plans to help it along while taking steps to ensure its quality.

South Korea's Green Cross says planned China stem cell plant fits demand forecasts

South Korea's Green Cross Holdings said its planned manufacturing operations in China dedicated to cell therapies, including T cells and stem cells for treating serious diseases, fits in with expected growing demand in for the products.

India works with Hilleman to help industry avoid waste in vaccines stockpile

The Drug Controller General of India, G.N. Singh, told India Today the government has been working with Hilleman on a proposal to research and develop formulations of oral rotavirus vaccines that are thermostable across a variety of temperatures and environmental conditions.

Israeli court tells Teva to return Copaxone, pay Proneuron; more ammo for Mylan?

An Israeli court ordered Teva Pharmaceutical to not only return the Copaxone (glatiramer acetate) multiple sclerosis drug it licensed from Proneuron Biotechnologies but also return 14 indications it received for other nervous system drugs. Oh, and pay Proneuron the equivalent of $128,666 as well.

Higher wages in India eating quickly into low-cost generic manufacturing model

Is the law of unintended consequences about to be visited on the drug industry in India, much as it already has in neighbor China? There is evidence a middle-class is rising in India, threatening its attraction as a low-priced place for outsourced drug production.

Japan's Panasonic joins Toshiba in rush to medical devices

Japan's Panasonic, one of the nation's large electronics companies making the switch to the healthcare market, plans to make its move in a big way, building its workforce from 2,000 to 20,000 by the end of fiscal year 2018. Its idea is to offer eldercare and related facilities and equipment.

India mulls adopting international standards on drug inspections, manufacturing

India's pharmaceutical regulators are considering whether to take the rigid steps necessary to join international drug inspection systems. The actions are considered necessary if India is to become more of an exporting nation, but some pharmas are cautious.